Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursoplus vs UDCA vs Placebo in Compensated Chronic Liver Disease
NCT05849558Phase 4Unknown
- Sponsor
- Minapharm Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ursodeoxycholic acid and silymarin in chronic liver disease (CLD) (3 arms), sponsored by Minapharm Pharmaceuticals. Primary endpoints: Change in Total Serum Bilirubin at 6 months, Change in Direct Serum Bilirubin at 6 months and 1 more. Status: unknown.
02
Drugs
ursodeoxycholic acidsilymarin
03
Conditions
chronic liver disease (CLD)
Beyond the preview
Go deeper on NCT05849558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849558.